Apostle MiniMax technology has been used and cited in this study:
- Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Christine D. Palmer, Amy R. Rappaport, Matthew J. Davis, et al. Nature Medicine volume 28, pages 1619–1629 (2022)
- Download PDF
